Design of temozolomide-loaded proliposomes and lipid crystal nanoparticles with industrial feasible approaches: comparative assessment of drug loading, entrapment efficiency, and stability at plasma pH

References

• Andrasi, M., et al., 2010. Analysis and stability study of temozolomide using capillary electrophoresis. Journal of chromatography B, 878 (21), 1801–1808.
   PubMed Web of Science ®Google Scholar
• Baker, S.D., et al., 1999. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clinical cancer research, 5, 309–317.
   PubMed Web of Science ®Google Scholar
• Bei, D., et al., 2010. Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization, 11, 0–6.
   Google Scholar
• Chobisa, D., et al., 2018. Development and characterization of an organic solvent free, proliposomal formulation of Busulfan using quality by design approach. International journal of pharmaceutics., 535 (1–2), 360–370.
   PubMed Web of Science ®Google Scholar
• De, A., et al., 2018. Smart niosomes of temozolomide for enhancement of brain targeting. Nanobiomedicine, 5, 184954351880535.
   Google Scholar
• Elhissi, A.M.A., et al., 2012. A study of size, microscopic morphology, and dispersion mechanism of structures generated on hydration of proliposomes a study of size, microscopic morphology, and dispersion mechanism of structures generated on hydration of proliposomes. Journal of dispersion science and technology, 33 (8), 1121–1126.
   Web of Science ®Google Scholar
• Friedman, H.S., Kerby, T., Fields, S., Zilisch, J.E.; The Brain Tumor Center at Duke 1999. Temozolomide and treatment of malignant glioma 1. Cancer, 85 (5), 1160–2597.
   PubMed Web of Science ®Google Scholar
• Ganipineni, L.P., Danhier, F., and Préat, V., 2018. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. Journal of controlled release, 281, 42–57.
   PubMed Web of Science ®Google Scholar
• Gao, J., et al., 2015. Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. Drug discoveries & therapeutics, 9 (3), 205–212.
   PubMed Web of Science ®Google Scholar
• Hu, J.U.N., et al., 2016. Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells. International journal of molecular medicine, 37 (3), 690–702.
   PubMed Web of Science ®Google Scholar
• Jigar, V., et al., 2018. Formulation and statistical optimization of intravenous Temozolomide loaded PEGylated liposomes to treat glioblastoma multiforme by three level factorial design. Drug development and industrial pharmacy, 44, 923–933.
   PubMed Web of Science ®Google Scholar
• Jin, S., et al., 2014. Preparation and evaluation of cyclosporin A-containing proliposomes: a comparison of the supercritical antisolvent process with the conventional film method. International journal of nanomedicine, 9, 5079–5091.
   PubMed Web of Science ®Google Scholar
• Joseph, E., and Singhvi, G., 2019. Multifunctional nanocrystals for cancer therapy: a potential nanocarrier. In: A.M. Grumezescu, ed. Nanomaterials for drug delivery and therapy. William Andrew Publishing, 91–116.
   PubMedGoogle Scholar
• Khan, A., et al., 2016. Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses. Molecular pharmaceutics, 13 (11), 3773–3782.
   PubMed Web of Science ®Google Scholar
• Khosa, A., Krishna, K.V., and Dubey, S.K., 2020. Chapter 15: lipid nanocarriers for enhanced delivery of temozolomide to the brain. Drug delivery system, 2059, 285–298.
   Google Scholar
• Khosa, A., Saha, R.N., and Singhvi, G., 2019. Drug delivery to the brain. In: A.M. Grumezescu, ed. Nanomaterials for drug delivery and therapy. William Andrew Publishing, 461–514.
   Google Scholar
• Kim, D., et al., 2015. A simple evaporation method for large-scale production of liquid crystalline lipid nanoparticles with various internal structures. ACS applied materials & interfaces, 7 (36), 20438–20446.
   PubMed Web of Science ®Google Scholar
• Kingdom, U., and Corporation, S., 2000. Oncologist the temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of. Advanced metastatic melanoma oncologist, 5, 144–151.
   Google Scholar
• Płaczek, M., and Kosela, M., 2016. Microscopic methods in analysis of submicron phospholipid dispersions. Acta pharmaceutica, 66 (1), 1–22.
   PubMed Web of Science ®Google Scholar
• Kumara, B.C., and Parthiban, S., 2015. Proliposome: a novel approach to carrier drug. International journal of biopharmaceutics, 6, 98–106.
   Google Scholar
• Lee, S.Y., 2016. ScienceDirect temozolomide resistance in glioblastoma multiforme. Genes & diseases, 3 (3), 198–210.
   PubMed Web of Science ®Google Scholar
• Messaoudi, K., Clavreul, A., and Lagarce, F., 2015. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug discovery today, 20 (7), 899–905.
   PubMed Web of Science ®Google Scholar
• Nekkanti, V., and Kalepu, S., 2015. Recent advances in liposomal drug delivery: A. Pharmaceutical nanotechnology, 3 (1), 35–55.
   Google Scholar
• Nordling-david, M.M., et al., 2017. Liposomal temozolomide drug delivery using convection enhanced delivery. Journal of controlled release, 261, 138–146.
   PubMed Web of Science ®Google Scholar
• Patel, B.K., and Parikh, R.H., 2016. Formulation development and evaluation of temozolomide loaded hydrogenated soya phosphatidylcholine liposomes for the treatment of brain cancer. Asian journal of pharmaceutical and clinical research., 9, 340–340.
   Google Scholar
• Qu, J., et al., 2016. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles. Drug delivery, 23 (9), 3408–3416.
   PubMed Web of Science ®Google Scholar
• Silva, G.S., et al., 2017. Characterisation of curcumin-loaded proliposomes produced by coating of micronised sucrose and hydration of phospholipid powders to obtain multilamellar liposomes. International journal of food science & technology, 52 (3), 772–780.
   Web of Science ®Google Scholar
• Singhvi, G., Banerjee, S., and Khosa, A., 2018. Lyotropic liquid crystal nanoparticles: a novel improved lipidic drug delivery system. In: A.M. Grumezescu, ed. Organic materials as smart nanocarriers for drug delivery. William Andrew Publishing, 471–517.
   Google Scholar
• Singhvi, G., et al., 2020. Nanocarriers as potential targeted drug delivery for cancer therapy. In: H. Daima, N. PN, S. Ranjan, N. Dasgupta, and E. Lichtfouse, eds. Nanoscience in medicine vol. 1. environmental chemistry for a sustainable world. Cham: Springer, 51–88.
   Google Scholar
• Sułkowski, W.W., et al., 2005. The influence of temperature, cholesterol content and pH on liposome stability. Journal of Molecular Structure, 744, 737–747.
   Web of Science ®Google Scholar
• Sun, D., Kang, S., Liu, C., Lu, Q., Cui, L., and Hu, B.; Department of Ultrasound in Medicine, Shanghai Jiao tong University Affiliated sixth People's Hospital, Shanghai Institute of Ultrasound in Medicine, Shanghai 200233, China, 2016. Effect of zeta potential and particle size on the stability of SiO2 nanospheres as carrier for ultrasound imaging contrast agents. International journal of electrochemical science, 11, 8520–8529.
   Web of Science ®Google Scholar
• Sun T. 2011. CHMP assessment report. 44.
   Google Scholar
• Taira, M.C., et al., 2004. Stability of liposomal formulations in physiological conditions for oral drug delivery stability of liposomal formulations in physiological. Drug delivery, 11 (2), 123–128.
   PubMed Web of Science ®Google Scholar
• Tosoni, A., and Franceschi, E., 2016. Relapsed glioblastoma: treatment strategies for initial and subsequent recurrences. Current treatment options in oncology, 17 (9), 49.
   PubMed Web of Science ®Google Scholar
• Van Tellingen, O., et al., 2015. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug resistance updates, 19, 1–12.
   PubMed Web of Science ®Google Scholar
• Yosra, S.R., et al., 2015. Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer ‘s disease: pharmaceutical, biological, and toxicological studies. International journal of nanomedicine, 10, 5459–5473.
   PubMed Web of Science ®Google Scholar